Therapeutics startup Celularity announced this morning that it has received FDA clearance to begin a clinical trial of a proposed stem cell treatment against COVID-19 by TheAlexKnapp
“By administering our NK cells to patients, we are acting to ‘flatten the viral titer curve,’ so the patient’s adaptive immune system can get in gear and do the job of clearing the virus,” he says.
It’s a strategy that’s earned the company support from investors like Bill Maris at Section 32, Sorrento Therapeutics, and former Apple CEO John Sculley. According to Pitchbook, the company has raised over $327 million in backing to date.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
The $94 billion fitness industry is reinventing itself as Covid-19 spreadsGyms and fitness studios are largely dependent on physical locations and on-site staff. But the spread of coronavirus has shut their doors -- and inspired creativity and flexibility to adjust to a new reality.
続きを読む »
How Brands Can Successfully Engage With Consumers Quarantined Due To COVID-19Here's how brands can successfully engage with consumers quarantined due to COVID-19:
続きを読む »
Union says 3 UPS employees test positive for COVID-19 at same Massachusetts facilityIn addition to the 3 UPS workers in Chelmsford, 2 dozen others are under doctor-ordered quarantine, according to their union.
続きを読む »
‘A lot of people are scared’: U.K. health care workers share struggles of COVID-19 fightWATCH: Health care workers from the U.K. share video diaries of their struggles on the front lines against COVID-19.
続きを読む »
COVID-19 vaccine candidates: 6 front-runners
続きを読む »